Scinai Immunotherapeutics Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
31
- Stock Symbol
-
SCNI
- Share Price
-
$3.40
- (As of Monday Closing)
Scinai Immunotherapeutics General Information
Description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
Contact Information
Website
www.scinai.comCorporate Office
- Jerusalem BioPark Building, 2nd Floor
- Hadassah Ein Kerem Campus
- Jerusalem
- Israel
Corporate Office
- Jerusalem BioPark Building, 2nd Floor
- Hadassah Ein Kerem Campus
- Jerusalem
- Israel
Scinai Immunotherapeutics Stock Performance
As of 02-Dec-2024, Scinai Immunotherapeutics’s stock price is $3.40. Its current market cap is $2.9M with 853K shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.40 | $3.44 | $2.23 - $8.92 | $2.9M | 853K | 27.2K | $2.40 |
Scinai Immunotherapeutics Financials Summary
As of 30-Sep-2024, Scinai Immunotherapeutics has a trailing 12-month revenue of $452K.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 20,637 | 16,036 | 14,721 | 54,754 |
| Revenue | 452 | 0 | 0 | 0 |
| EBITDA | (3,881) | (6,109) | (8,285) | (10,887) |
| Net Income | 4,696 | (6,500) | (5,796) | (8,206) |
| Total Assets | 12,261 | 17,472 | 27,067 | 32,036 |
| Total Debt | 1,227 | 20,561 | 21,542 | 28,985 |
Scinai Immunotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Scinai Immunotherapeutics Comparisons
Industry
Financing
Details
Scinai Immunotherapeutics Competitors (9)
One of Scinai Immunotherapeutics’s 9 competitors is aVaxziPen, a Corporation company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| aVaxziPen | Corporation | Abingdon, United Kingdom | ||||
| Bluebird Bio | Formerly VC-backed | Somerville, MA | ||||
| VBI Vaccines | Corporate Backed or Acquired | Cambridge, MA | ||||
| Sinovac | Corporation | Beijing, China | ||||
| NH TherAguix | Formerly VC-backed | Villeurbanne, France |
Scinai Immunotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Scinai Immunotherapeutics Patents
Scinai Immunotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200000910-A1 | Compositions of multimeric-multiepitope influenza polypeptides and their production | Inactive | 03-Apr-2014 | ||
| AU-2015242154-B2 | Compositions of multimeric-multiepitope influenza polypeptides and their production | Inactive | 03-Apr-2014 | ||
| CA-2944768-A1 | Compositions of multimeric-multiepitope influenza polypeptides and their production | Active | 03-Apr-2014 | ||
| US-10426828-B2 | Compositions of multimeric-multiepitope influenza polypeptides and their production | Active | 03-Apr-2014 | ||
| EP-3125931-A1 | Compositions of multimeric-multiepitope influenza polypeptides and their production | Inactive | 03-Apr-2014 | A61K39/12 |
Scinai Immunotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Scinai Immunotherapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Scinai Immunotherapeutics FAQs
-
When was Scinai Immunotherapeutics founded?
Scinai Immunotherapeutics was founded in 2003.
-
Where is Scinai Immunotherapeutics headquartered?
Scinai Immunotherapeutics is headquartered in Jerusalem, Israel.
-
What is the size of Scinai Immunotherapeutics?
Scinai Immunotherapeutics has 31 total employees.
-
What industry is Scinai Immunotherapeutics in?
Scinai Immunotherapeutics’s primary industry is Pharmaceuticals.
-
Is Scinai Immunotherapeutics a private or public company?
Scinai Immunotherapeutics is a Public company.
-
What is Scinai Immunotherapeutics’s stock symbol?
The ticker symbol for Scinai Immunotherapeutics is SCNI.
-
What is the current stock price of Scinai Immunotherapeutics?
As of 02-Dec-2024 the stock price of Scinai Immunotherapeutics is $3.40.
-
What is the current market cap of Scinai Immunotherapeutics?
The current market capitalization of Scinai Immunotherapeutics is $2.9M.
-
What is Scinai Immunotherapeutics’s current revenue?
The trailing twelve month revenue for Scinai Immunotherapeutics is $452K.
-
Who are Scinai Immunotherapeutics’s competitors?
aVaxziPen, Bluebird Bio, VBI Vaccines, Sinovac, and NH TherAguix are some of the 9 competitors of Scinai Immunotherapeutics.
-
What is Scinai Immunotherapeutics’s annual earnings per share (EPS)?
Scinai Immunotherapeutics’s EPS for 12 months was $2.40.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
